Waters (WAT) to Post Quarterly Earnings on Tuesday

Waters (NYSE:WAT) is anticipated to issue its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of $3.01 per share and revenue of $1.6223 billion for the quarter. Waters has set its Q2 2026 guidance at 2.950-3.050 EPS and its FY 2026 guidance at 14.400-14.600 EPS. Parties may visit the the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 8:00 AM ET.

Waters (NYSE:WAT) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $2.70 EPS for the quarter, beating analysts’ consensus estimates of $2.31 by $0.39. Waters had a net margin of 11.91% and a return on equity of 15.60%. The business had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.20 billion. During the same quarter in the previous year, the business posted $2.25 EPS. Waters’s quarterly revenue was up 91.4% on a year-over-year basis. On average, analysts expect Waters to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

Waters Stock Down 0.7%

Waters stock opened at $377.75 on Friday. The company has a current ratio of 1.79, a quick ratio of 1.13 and a debt-to-equity ratio of 0.32. The firm’s fifty day moving average price is $369.30 and its two-hundred day moving average price is $345.48. The firm has a market capitalization of $37.09 billion, a price-to-earnings ratio of 48.00, a price-to-earnings-growth ratio of 2.28 and a beta of 1.20. Waters has a 1-year low of $275.05 and a 1-year high of $414.15.

Institutional Trading of Waters

A number of hedge funds have recently bought and sold shares of WAT. Zions Bancorporation National Association UT grew its stake in Waters by 121.2% in the 4th quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier’s stock valued at $28,000 after purchasing an additional 40 shares during the period. DV Equities LLC bought a new position in Waters during the fourth quarter valued at $32,000. Itau Unibanco Holding S.A. boosted its position in Waters by 39.6% during the fourth quarter. Itau Unibanco Holding S.A. now owns 155 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 44 shares during the period. MUFG Securities EMEA plc purchased a new position in shares of Waters in the second quarter worth about $61,000. Finally, State of Wyoming bought a new stake in shares of Waters in the second quarter valued at approximately $75,000. 94.01% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

WAT has been the subject of a number of analyst reports. Royal Bank Of Canada assumed coverage on Waters in a research note on Wednesday, July 8th. They set an “outperform” rating and a $435.00 price target for the company. Wolfe Research started coverage on Waters in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $425.00 target price on the stock. Bank of America upped their price target on Waters from $370.00 to $400.00 and gave the stock a “neutral” rating in a report on Tuesday, June 2nd. Wells Fargo & Company raised their price objective on Waters from $355.00 to $370.00 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Finally, Morgan Stanley lifted their price objective on shares of Waters from $350.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday, July 9th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $401.60.

About Waters

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.